

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 石四藥集團有限公司 SSY Group Limited

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2005)**

## **VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT**

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approval for drug clinical trial for Roflumilast Tablets from the China Food and Drug Administration. Roflumilast is mainly used as a treatment for serious chronic respiratory obstructive pulmonary disease with chronic bronchitis. Roflumilast has not been sold in the Mainland market and is a type 3.1 chemical drug.

In addition, the Board also announces that the Group has obtained the production approval for five-layer infusion solution soft bag package for Sodium Bicarbonate Injection, and the production approval for polypropylene infusion solution bottle package for Pediatric Electrolyte Supplements Injection, adding two therapeutic infusion solution products for the Group.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board  
**Chow Hing Yeung**  
*Company Secretary*

Hong Kong, 17 November 2015

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.*